journal
Journals Journal of Ocular Pharmacology...

Journal of Ocular Pharmacology and Therapeutics

https://read.qxmd.com/read/38117666/intravitreal-dexamethasone-as-a-rescue-for-anti-vascular-endothelial-growth-factor-therapy-in-neovascular-age-related-macular-degeneration-with-persistent-disease-activity-and-high-treatment-demand
#21
JOURNAL ARTICLE
Marlena Pietzuch, Irmela Mantel, Aude Ambresin, Christoph Tappeiner, Dana Nagyova, Guy Donati, Isabel B Pfister, Christin Schild, Justus G Garweg
Purpose: To assess the impact of switching to, or adding, an intravitreal dexamethasone implant (Dex; Ozurdex® ) in anti-vascular endothelial growth factor (VEGF) therapy on disease stability and treatment intervals in eyes with neovascular age-related macular degeneration (nAMD) and persistent disease activity and high treatment demand. Methods: This retrospective noncomparative multicenter longitudinal case series included pseudophakic eyes with nAMD and persistent retinal fluid despite regular anti-VEGF therapy (ranibizumab or aflibercept) that received at least 1 intravitreal Dex implant...
December 20, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/38100078/effects-of-diquafosol-sodium-ophthalmic-solution-on-tear-film-matrix-metallopeptidase-9-and-corneal-nerve-density-in-patients-with-type-2-diabetic-dry-eye
#22
JOURNAL ARTICLE
Guanghao Qin, Jiayan Chen, Liangzhe Li, Yifan Qi, Yimeng Chen, Qing Zhang, Yi Wu, Yue You, Lanting Yang, Naici Guo, Salissou Moutari, Shaochong Bu, Jonathan E Moore, Ling Xu, Wei He, Sile Yu, Xingru He, Emmanuel Eric Pazo
Purpose: Diabetes mellitus has been associated with increased dry eye disease (DED) and exacerbates DED's pathology. This preliminary short-term study aimed to evaluate the effects of 3% Diquafosol Sodium ophthalmic solution (DQS) on ocular surface inflammation and corneal nerve density in diabetic dry eye (DDE) patients. Methods: In this perspective, participants used 1 drop of 3% DQS (Diquas; Santen Pharmaceutical Co., Ltd., Osaka, Japan) 6 times daily for 8 weeks. Non-invasive tear breakup time (NITBUT), tear film lipid layer (TFLL), conjunctival hyperemia [redness score (RS)], corneoconjunctival staining (CFS), corneal sensitivity (CS), Meibomian gland quality (MGQ) and Meibomian gland expressibility (MGEx), corneal nerve fiber density (CNFD), and Standard Patient Evaluation Eye Dryness (SPEED) questionnaire were assessed at baseline, at weeks 4, and up to 8 weeks...
December 13, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/38088745/ncx-470-reduces-intraocular-pressure-more-effectively-than-lumigan-in-dogs-and-enhances-conventional-and-uveoscleral-outflow-in-non-human-primates-and-human-trabecular-meshwork-schlemm-s-canal-constructs
#23
JOURNAL ARTICLE
Corinna Galli, Elena Bastia, Douglas A Hubatsch, Carol Toris, Shan Fan, Andrea Unser, Feryan Ahmed, Karen Y Torrejon, Francesco Impagnatiello
Purpose: To determine NCX 470 (0.1%) and Lumigan® (bimatoprost ophthalmic solution, 0.01%-LUM) intraocular pressure (IOP)-lowering activity after single or repeated (5 days) dosing along with changes in aqueous humor (AH) dynamics. Methods: Ocular hypotensive activity of NCX 470 and LUM was compared with vehicle (VEH) in Beagle dogs using TonoVet® . Non-human primates (NHP) and bioengineered three-dimensional (3D) human Trabecular Meshwork/Schlemm's Canal (HTM/HSC™) constructs exposed to transforming growth factor- β 2 (TGF β 2) were used to monitor NCX 470 and LUM-induced changes in AH dynamics...
December 12, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/38052063/nanotechnology-in-retinal-disease-current-concepts-and-future-directions
#24
JOURNAL ARTICLE
Nalin J Mehta, Sachin N Mehta
The retina is one of the most complex and extraordinary human organs affected by genetic, metabolic, and degenerative diseases, resulting in blindness for ∼1.3 million people in the United States and over 40 million people worldwide. This translates into a huge loss of productivity, especially among younger patients with inherited retinal diseases (IRDs) and diabetic retinopathy. Age-related macular degeneration accounts for 90% of all blindness cases worldwide. The prevalence of this condition is projected to reach over 5 million individuals over the next 3 decades...
December 5, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37579061/clinical-efficacy-of-omidenepag-isopropyl-for-primary-open-angle-glaucoma-normal-tension-glaucoma-or-ocular-hypertension-a-meta-analysis
#25
JOURNAL ARTICLE
Hou-Ting Kuo, Cyuan-Yi Yeh, Alan Y Hsu, Jennifer Hui-Chun Ho, Chun-Ju Lin, Yi-Yu Tsai
Purpose: To investigate the clinical efficacy of omidenepag isopropyl (OMDI) among glaucoma patients in terms of increased intraocular pressure (IOP) changes through a meta-analysis. Methods: Studies investigating the clinical efficacy of OMDI toward glaucoma patients were systemically searched. Inclusion criteria include recruiting studies that consisted of glaucoma or normal tension glaucoma patients who received OMDI treatment at least 4 weeks in duration. The primary outcome was to compare changes in IOP levels at baseline before OMDI treatment and after OMDI treatment...
December 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/38011696/the-effectiveness-and-safety-of-intravitreal-injections-of-voriconazole-in-the-treatment-of-fungal-endophthalmitis-a-systematic-review
#26
JOURNAL ARTICLE
Yue Xie, Xin Wang, Zichao Ji, Guangyao Li, Chao Zhang
Background: Fungus endophthalmitis is a rare and serious infection that is treated with systemic and topical antifungal drugs. There is no clear consensus on the treatment of fungal endophthalmitis with intravitreal injections (IVIs) of voriconazole. This systematic review aims to summarize the literature on IVIs of voriconazole for fungal endophthalmitis. Methods: We conducted a systematic review of the literature to determine the effectiveness and safety of IVIs of voriconazole in the treatment of fungal endophthalmitis...
November 24, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37922455/a-comparative-preclinical-evaluation-of-a-novel-difluprednate-0-04-bid-ophthalmic-solution-and-marketed-0-05-qid-ophthalmic-emulsion
#27
JOURNAL ARTICLE
Ajay J Khopade, Arindam Halder, Vivek Patel, Harsh Shah, Ankit Shah, Vinod Burade, Rishit Zalawadia, Alpesh Patel, Chandan Awati, Murlidhar Zope
Purpose: The purpose of this study was to compare the efficacy, and ocular pharmacokinetics of a new 0.04% w/v bis in die means twice a day (BID) ophthalmic solution and marketed 0.05% w/v quater in die means four times a day (QID) ophthalmic emulsion of difluprednate in New Zealand white (NZW) rabbits. Methods: The preclinical proof of concept was established in paracentesis-induced acute inflammation, endotoxin-induced acute uveitis, and bovine serum albumin-induced chronic uveitis in NZW rabbit animal models...
November 6, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37910805/evaluation-of-the-impact-of-meibomian-gland-dysfunction-using-a-novel-patient-reported-outcome-instrument
#28
JOURNAL ARTICLE
Layla Ajouz, Joelle Hallak, Rupali Naik, Ashley Nguyen, Cathy Zhao, Michael R Robinson, Kelly K Nichols
Purpose: This study was intended to characterize the impact of meibomian gland dysfunction (MGD) on patients' quality of life. Methods: In this prospective, multicenter, noninterventional clinical study (NCT01979887), eligible individuals (age ≥40 years; absence of uncontrolled ocular/systemic disease) were categorized, based on composite grading of ocular symptoms, Schirmer score, and meibum quality, into (1) non-MGD, (2) mild/moderate MGD, or (3) severe MGD cohorts. The MGD Impact Questionnaire (MGD IQ), a 10-item patient-reported outcome measure, was self-administered at clinic visit on day 1, and readministered on day 22 to assess intervisit agreement regarding MGD IQ responses...
November 1, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37738326/rock-inhibitors-as-an-alternative-therapy-for-corneal-grafting-a-systematic-review
#29
REVIEW
Subramanyam Polopalli, Achintya Saha, Pakter Niri, Mohit Kumar, Parikshit Das, Dev Vrat Kamboj, Pronobesh Chattopadhyay
Currently, corneal blindness is affecting >10 million individuals worldwide, and there is a significant unmet medical need because only 1.5% of transplantation needs are met globally due to a lack of high-quality grafts. In light of this global health disaster, researchers are developing corneal substitutes that can resemble the human cornea in vivo and replace human donor tissue. Thus, this review examines ROCK (Rho-associated coiled-coil containing protein kinases) inhibitors as a potential corneal wound-healing (CWH) therapy by reviewing the existing clinical and nonclinical findings...
November 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37906159/eyes-on-new-product-development
#30
JOURNAL ARTICLE
Gary D Novack
No abstract text is available yet for this article.
October 31, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37878373/interspecialty-opioid-prescribing-patterns-in-ophthalmology-following-declaration-of-a-public-health-emergency
#31
JOURNAL ARTICLE
Hassaam S Choudhry, Aman M Patel, Aretha Zhu, Sri Guttikonda, Anam Shaikh, Hadeel S Sadek, Christopher W Seery, Mohammad H Dastjerdi
Purpose: Previous literature has investigated opioid prescription trends in ophthalmology at large, however, little has been done looking at differences between subspecialties. We evaluate if significant trends exist among subspecialties in opioid prescribing patterns. This study aims to illuminate potential over-usage of opioids in ophthalmology that could compromise patient quality of life. Methods: Medicare data and "National Plan and Provider Enumeration System (NPPES) Downloadable File" were queried for cases of ophthalmologists with nonsuppressed opioid prescription data from 2014 to 2019...
October 25, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37856655/eyes-on-new-product-development
#32
JOURNAL ARTICLE
Gary D Novack
No abstract text is available yet for this article.
October 19, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37851489/investigation-of-needle-characteristics-using-an-animal-model-for-improved-outcomes-in-anterior-chamber-paracentesis
#33
JOURNAL ARTICLE
Reed Brockstein, Yu-Chang Chen, Curtis Marshall, Lindsay Kwok, Athanacia Papoutsis, Thomas Wei, Deana C McDonagh, Stephen Sanderson, Richard Mental, Leanne T Labriola
Background/Aims: The current standard of care to perform an anterior chamber paracentesis involves the use of a multipurpose market needle and syringe. The use of standard needles for this purpose may result in injury to the patient due to increased force with insertion and increased globe displacement during the procedure. This research investigates the current market needle characteristics and the impact of each needle characteristic on force. Methods: Several comparative trials were conducted to evaluate the needles...
October 17, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37797226/eyes-on-the-prize-decoding-the-ophthalmic-product-regulations-and-intricacies-of-the-u-s-food-and-drug-administration-approval
#34
JOURNAL ARTICLE
Khemraj Hirani, Mylarrao Bansinath, Rahul Mittal, Joana R N Lemos, Emily Adis, Priyanka Poojari, Jane Margaret Igoe, Marcio R Soares, Sanjoy Bhattacharya, Roy E Weiss
The dynamic and continuously evolving field of ophthalmology necessitates rigorous regulatory oversight in the United States. This review outlines the multifaceted Food and Drug Administration's (FDA) approval process for ophthalmic products, detailing the classifications, pathways, and regulatory compliance for devices, drugs, biologics, and combination products. Particular emphasis is placed on distinct frameworks for Class I, II, and III devices, as well as regulations for drugs, biologics, and combination products...
October 5, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37861412/eyes-on-new-product-development
#35
JOURNAL ARTICLE
Gary D Novack
No abstract text is available yet for this article.
October 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37861411/regeneration-and-vision-restoration
#36
JOURNAL ARTICLE
Matthew B Veldman, Sanjoy K Bhattacharya
No abstract text is available yet for this article.
October 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37861410/aopt-xv-biennial-meeting-restoring-vision-through-regeneration
#37
EDITORIAL
Zhigang He
No abstract text is available yet for this article.
October 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37733327/recent-insights-into-the-etiopathogenesis-of-diabetic-retinopathy-and-its-management
#38
JOURNAL ARTICLE
Arpon Biswas, Abhijit Deb Choudhury, Sristi Agrawal, Amol Chhatrapati Bisen, Sachin Nashik Sanap, Sarvesh Kumar Verma, Mukesh Kumar, Anjali Mishra, Shivansh Kumar, Mridula Chauhan, Rabi Sankar Bhatta
Purpose: Diabetic retinopathy (DR) is a microvascular retinal disease associated with chronic diabetes mellitus, characterized by the damage of blood vessels in the eye. It is projected to become the leading cause of blindness, given the increasing burden of the diabetic population worldwide. The diagnosis and management of DR pose significant challenges for physicians because of the involvement of multiple biochemical pathways and the complexity of ocular tissues. This review aims to provide a comprehensive understanding of the molecular pathways implicated in the pathogenesis of DR, including the polyo pathway, hexosamine pathway, protein kinase C (PKC), JAK/STAT signaling pathways, and the renin-angiotensin system (RAS)...
September 21, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37733302/development-of-anterior-segment-focused-biologic-therapies-to-regenerate-corneal-tissue-for-the-treatment-of-disease-drug-development-experience
#39
JOURNAL ARTICLE
Cheryl Rowe-Rendleman, David Eveleth, Jeffrey L Goldberg, Ula Jurkunas, Naoki Okumura, Daniel Dawson, Onkar B Sawant
On February 24-27, 2021, the Association for Ocular Pharmacology and Therapeutics (AOPT) held its 15th biennial scientific meeting online. The meeting was organized by Dr. Sanjoy Bhattacharya of the University of Miami in conjunction with the board of trustees of the AOPT. The 3-day conference was attended by academic scientists, clinicians, and industry and regulatory professionals. The theme of the meeting was Restoring Vision through Regeneration and it was sponsored, in part, by the National Institutes of Health, Bright Focus, Regeneron, and Santen (USA)...
September 21, 2023: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/37729070/mg132-attenuates-the-retinal-vascular-injury-through-the-upregulation-of-nrf2-expression
#40
JOURNAL ARTICLE
Peipei Wang, Shipei Fan, Xin Hu, Li Luo, Jia Ying, Jun Li
Purpose: This study clarifies the beneficial effects of MG132, a proteasomal inhibitor, on retinal vascular injury mediated by diabetes-induced oxidative stress through nuclear factor erythroid 2-related factor 2 ( Nrf2 ). Methods: Diabetic rats and control animals were randomly assigned to receive MG132 or vehicle for 24 weeks, and human retinal endothelial cells (HRECs) were incubated with normal or high glucose with or without MG132. 26S proteasome activity in the rat retinas or cultured HRECs was measured using Suc-LLVY-7-amido-4-methylcoumarin...
September 20, 2023: Journal of Ocular Pharmacology and Therapeutics
journal
journal
32321
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.